Clinical Trials Browser

Phase 2 × nimotuzumab × 90 days × Clear all

NCT07457528 2026-03-11

Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

Phase 2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07354984 2026-01-21

PIONEER-HN

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07312578 2025-12-31

Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma

Phase 2 Enrolling by invitation

Gastrointestinal

Esophageal Squamous Cell Carcinoma